BioNano Genomics Inc (NASDAQ: BNGO) is at the forefront of the market this morning for good reason. The company announced the publication of a study on autism risk genes. Here’s what’s going on:
As mentioned above, BioNano Genomics has a great start to the pre-market hours trading session this morning for good reason. The company announced the publication of an analysis of Professor Temple Grandin’s genome in one of the most comprehensive assessments of a single genome of a high-functioning individual with Autism Spectrum Disorder.
BNGO further stated that by using the Lineagen suite of genetic tests tailored to individuals with ASD and other child developmental disorders, and by sequencing the entire genome, the study found new variants in known autism risk genes and other genetic variants identified as important to their health and wellbeing.
The company said that despite Dr. . Because of Grandin’s high level of function and acute awareness of how her autism manifests, these results have resulted in improved clinical management of many of her symptoms.
BNGO said that Dr. . Grandin was diagnosed with an autism spectrum disorder in childhood that was nonverbal until the age of three. She avoided physical contact and had difficulty socializing. Nevertheless, she overcame these challenges and became a world-famous doctoral student and author. In addition, she was named one of the Top 10 College Professors by CEOWORLD Magazine.
When I originally asked for genetic testing, I had no idea that the test I was getting for autism information would provide me with valuable information for other health problems. It is clearly beneficial for individuals to undergo genetic testing. People with autism like me may learn vital information to help make medical decisions that could potentially save their lives while finding a genetic link to autism. Testing for people with autism wasn’t commonplace in my teens or early adulthood, which is too bad as this practice will advance the medical community’s understanding of autism and health risks.
The above statement was followed up by Erik Holmin, PhD, CEO at BioNano Genomics. He had the following to offer:
This publication demonstrates the importance of genetic testing for ASD and neurodevelopmental disorders. ASD is usually diagnosed based on a child’s behavior, and only 3% of children diagnosed with ASD receive clinical genetic testing recommended by a number of professional medical organizations, including the American College of Medical Genetics and Genomics and the American Academy of Pediatrics. The widespread adoption of genetic testing is important for patients and families as it creates a better understanding of ASD, but most importantly, it informs families and patients about immediate health risks associated with ASD that could personalize treatment options and potentially provide life-saving information.
We thank Dr. . Grandin for willingness to participate in this study. After Lineagen has become part of Bionano Genomics, we are expanding this study in the next phase to include a complete analysis of your genome using optical genome mapping (OGM) with Saphyr. The wide range of genetic variations among people with ASD makes it difficult for traditional tests to provide a diagnosis of the genetic condition. We expect that OGM with Saphyr will provide a more complete picture of the genomic variants that will provide actionable information that can potentially improve results.
According to TipRanks, there are currently three analysts looking at BNGO stocks and the opinions are very strong. Of the three analysts who cover the stock, two rate it as buy and one as hold.
However, it is important to remember that you should never blindly follow the opinions of experts, myself, analysts, or even Warren Buffet. Even so, it is a good idea to use these opinions as a source of validation for your own.
When you invest, you are taking a risk. At BioNano Genomics it is no different. Before buying, here are the top risks related to BNGO stocks:
While any investment involves risk, investing in BioNano Genomics is worth considering right now. Ultimately, the company is working to resolve one of the most pressing and widespread problems in pediatric medicine today, autism spectrum disorder.
While the disorder is very difficult to treat, data from this study will ultimately help BNGO find solutions to this large patient population that make the inventory difficult to ignore.
Bionano Genomics, NASDAQ: BNGO, Genomics, Autistic Spectrum Disorders, Autism, Temple Grandin, Genetics, NASDAQ, Stock
World News – USA – BNGO Stock: BioNano Genomics Flies On Publication – CNA Finances
. . Related title :
– BNGO stick: BioNano Genomics flies on release
– BNGO Stock Alert: Why Bionano Genomics Stock is shooting up again
– Bionano Genomics publishes study on autism risk genes after detailed analysis of the genome of Professor Temple . . .
– Bionano Genomics (BNGO) publishes study on autism risk genes after detailed analysis of the professor’s genome . . .
Donnez votre point de vue et aboonez-vous!
Votre point de vue compte, donnez votre avis
[maxbutton id= »1″]